DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,125,919 B2 Maloney Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,125,919 B2 Maloney Et Al US009 125919B2 (12) United States Patent (10) Patent No.: US 9,125,919 B2 Maloney et al. (45) Date of Patent: Sep. 8, 2015 (54) ACNETREATMENT POWDER FOUNDATION 6,475,500 B2 11/2002 Vatter et al. 6,491.953 B1 12/2002 Sojka et al. 6,524,598 B2 2/2003 Sunkel et al. (75) Inventors: John D. Maloney, Salisbury, NC (US); 6,599,513 B2 7/2003 Deckers et al. Katherine Natalie Barger, Davidson, 6,696,049 B2 2/2004 Vatter et al. NC (US) 6,831,191 B2 12/2004 Chaudhuri 7,115,282 B2 10/2006 Shefer et al. (73) Assignee: EI LLC, Raleigh, NC (US) 7,166,273 B2 1/2007 Chaudhuri 7,208.460 B2 4/2007 Shefer et al. 7,247,323 B2 7/2007 George et al. (*) Notice: Subject to any disclaimer, the term of this 7,250,174 B2 7/2007 Lee et al. patent is extended or adjusted under 35 7,297,678 B2 11/2007 Kumar et al. U.S.C. 154(b) by 386 days. 7,304,177 B2 12/2007 Kleiman et al. 7,329,719 B2 2, 2008 Pavlin (21) Appl. No.: 12/639,851 2004/0219124 A1 1 1/2004 Gupta 2004/0234633 A1* 11/2004 Kim et al. ..................... 424,769 2005/0002996 A1* 1/2005 Sojka ............................ 424,445 (22) Filed: Dec. 16, 2009 2005, OO31658 A1* 2, 2005 Girier Dufournier et al. ............................. 424/401 (65) Prior Publication Data 2005/0129759 A1* 6/2005 Sojka . ... 424/469 2005/02268.30 A1* 10/2005 Fang ............................... 424,63 US 2010/O183528A1 Jul. 22, 2010 2005/0249720 A1* 11/2005 Perez ................. 424/94.65 2005/0265934 A1* 12/2005 Schumacher et al. .......... 424,59 Related U.S. Application Data 2006, O1988OO A1 9, 2006 Dilallo et al. 2007/007 1978 A1* 3/2007 Sojka et al. ........... 428/402.2 (60) Provisional application No. 61/138.436, filed on Dec. 2007/0258919 A1 1 1/2007 Angel et al. 17, 2008. 2008.0070875 A1 3/2008 Majewski et al. 2008/O138293 A1* 6/2008 Tamarkin et al. ............... 424/45 2008/0181920 A1* 7/2008 Buerger et al. ............... 424/401 (51) Int. Cl. 2008.0193393 A1 8/2008 Dayan A6IP 7/10 (2006.01) 2009, 0215723 A1* 8, 2009 Le ................................... 514.63 A6 IK 8/368 (2006.01) 2009/024615.6 A1* 10, 2009 Kunin ............................. 424/60 A61O I/00 (2006.01) A61O 1704 (2006.01) FOREIGN PATENT DOCUMENTS A6 IK3I/60 (2006.01) A6 IK 8/27 (2006.01) CN 1539.433 A 10, 2004 KR 1020030005485 A 1, 2003 A6 IK 8/29 (2006.01) WO WO95.04537 A1 2, 1995 A6 IK 8/35 (2006.01) WO WOOO733.74 A1 T 2000 A6 IK 8/8 (2006.01) A 6LX8/97 (2006.01) OTHER PUBLICATIONS A6 IK3I/2 (2006.01) Houston Healthcare, “Nonsteroidal Anti-Inflamatory Drugs'. http:// A6 IK3I/35 (2006.01) www.hhc.org/HealthTopics.aspx?chunkid=21396&lang=English A6 IK33/04 (2006.01) &db=hltip8, accessed Jan. 24, 2014.* A6 IK33/24 (2006.01) Mintel GNPD, "XP-002676188 Glowtion to Go Moisturizer, A6 IK33/30 (2006.01) Accessed online at GNPD Database (www.gmpd.com), Jun. 1999, pp. A6 IK 45/06 (2006.01) 1-2. A61O I/12 (2006.01) Mintel GNPD, "XP-002676203 Healing Powder”. Accessed online (52) U.S. Cl. at GNPD database (www.gnpd.com) Feb. 2008, pp. 1-2. CPC. A61 K3I/60 (2013.01); A61 K8/27 (2013.01); * cited by examiner A61K 8/29 (2013.01); A61K 8/35 (2013.01); A61K 8/368 (2013.01); A61 K8/8152 Primary Examiner — Bethany Barham (2013.01); A61K 8/97 (2013.01); A61 K3I/12 Assistant Examiner — Melissa Javier (2013.01); A61 K3I/315 (2013.01); A61 K (74) Attorney, Agent, or Firm — Hultquist, PLLC; Steven J. 33/04 (2013.01); A61 K33/24 (2013.01); A61 K Hultquist; Mary B. Grant 33/30 (2013.01); A61K 45/06 (2013.01); A61O I/I2 (2013.01); A61K 2800/56 (2013.01) (57) ABSTRACT (58) Field of Classification Search None Dry powder foundation formulations that include a sustained See application file for complete search history. release salicylic acid composition, an effective, buffering amount of one or more Salicylate ions, and one or more of Zinc (56) References Cited and titanium oxides, and pigments or colorants, are disclosed. The formulations provide both acne treatment and preven U.S. PATENT DOCUMENTS tion, and Sunblock protection. The formulation can also include other Sunblocking or Sunscreen agents to prevent 5.449,519 A 9, 1995 Wolfetal. 5,919,467 A * 7/1999 Jenkins et al. ................ 424/401 photoaging and Sunburn, such as avobenzone, and 3-ben 6,235,297 B1 5, 2001 Antonelli et al. Zophenone, and other cosmetically-acceptable active agents 6,331.305 B1 12/2001 Sang and excipients. 6,387,995 B1 5/2002 Sojka 6,416,748 B1 7/2002 Candau et al. 19 Claims, No Drawings US 9,125,919 B2 1. 2 ACNE TREATMENT POWDER FOUNDATION Because the composition provides salicylic acid in the form of a Sustained-release composition, the salicylic acid CROSS-REFERENCE TO RELATED remains effective for an extended period of time. Poly Pore APPLICATION 450SA, a polymeric formulation including salicylic acid in an allyl methacrylate crosspolymer, is a representative poly This is a U.S. non-provisional of U.S. Provisional Patent meric Sustained-release form of Salicylic acid, though other Application No. 61/138.436 filed on Dec. 17, 2008. The dis Sustained-release formulations can also be used. Further, as closure of the foregoing application is hereby incorporated anti-acne additives, the formulation includes one or more herein by reference in its respective entirety, for all purposes, salicylates, ideally isolated as an extract from willow bark and the priority of Such application is hereby claimed under 10 and/or aspen bark. In addition to the salicylic acid and one or the provisions of 35 USC 119. more salicylates, the formulation can also include other anti acne agents, including Sulfur, benzoyl peroxide, and resorci BACKGROUND OF THE INVENTION nol. 15 In addition to normal excipients found in dry powder foun Acne is the most common skin disorder in the US, and dations, the formulation includes Zinc oxide and/or titanium although this condition is generally associated with puberty, it dioxide as Sunblocking agents. The formulation can also is not confined to adolescence and can persist well into adult include other Sunblocking or Sunscreen agents to prevent hood. The acne condition is a complex one, impacted by a photoaging and Sunburn, such as avobenzone, and 3-ben number of intrinsic and extrinsic factors, and, as such, must be Zophenone. treated with a multifaceted approach. Treatment should The foundation formulation typically also includes colo address overproduction of sebum, hyperkeratinization, over rants/pigments, for example, inorganic colorants/pigments, growth of Pacnes, and the ultimate blockage and irritation of one example of which is a blend of iron oxide, bismuth the pilosebaceous follicle. Extrinsic factors, which exacer oxychloride, and mica. bate the acne condition, involve exfoliation via harsh abra 25 In one embodiment, the composition further includes one sives or mechanical scrubbing, UV exposure, and Some topi or more additional components, such as Zinc gluconate, cal and oral Substances. Active Powder Purity LS 9695, and pearl powder, such as Salicylic acid is a relatively mild beta-hydroxyacid, which PPP-100 pearl powder. is proven effective at correcting abnormal descquamation, the In one aspect of this embodiment, the formulation has the natural shedding of the outermost stratum corneum cells. Its 30 following ingredients, in the ranges of weight percentages treatment benefits extend beyond that of the acne condition to provided below in Table 1. include psoriasis, keratoses, and ichthyoses. By penetrating into the follicle, Salicylic acid encourages the sloughing of TABLE 1 dead skin cells and other cellular debris and, ultimately, clears Representative Formulation Ranges blockages. Further benefits of its exfoliating action are 35 improvements in skin texture and hyperpigmentation. Ingredient Range % wiw While there are a wide variety of products on the market Iron Oxide, Bismuth Oxychloride & Mica blend 40-75 containing salicylic acid for treating the acne condition, most Titanium Dioxide 5-40 are in the forms of lotions, creams, and liquids, including Zinc Oxide 5-35 liquid foundation makeup. Incorporation of salicylic acid into 40 Poly-Pore 450SA O.10-12.OO Salicylic Acid & Allyl Methacrylates Crosspolymer color foundations is advantageous, as it helps to clear current ABS White Willow Bark Extract Powder O.10-1O.OO breakouts while concealing them. Furthermore, continued Salix Nigra (Willow) Bark Extract use will help to preventfuture breakouts. Loose powder foun Phytocide Aspen Bark Extract Powder O.10-1O.OO dations are currently enjoying much popularity, as they Populus Tremuloides (Aspen) Bark Extract 45 Givobio GZn O.10-1O.OO impart a lightweight, natural feel on the skin while providing Zinc Gluconate great coverage, long wearability, oil absorption, and diffuse Active Powder Purity LS9695 O.10-1O.OO the appearance of blemishes and other skin imperfections. Exfoliance Bamboo O.10-1O.OO Providing a loose powder foundation with acne treatment Bambusa Arundinacea Stem Powder PPP-100 Pearl Powder O.10-1O.OO benefits would represent an improvement over an already Pearl Powder popular product type. 50 However, the presence of free salicylic acid may serve to irritate the skin. Accordingly, it would be advantageous to The foundation formulations combine the benefits of acne provide a loose powder foundation that provides the benefits treatment and UV protection with lightweight coverage. The of salicylic acid, while minimizing the degree of skin irrita foundation formulations combat acne by reducing & regulat tion.
Load more

Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • United States Patent Office Patented June 21, 1966 1
    3,257.276 United States Patent Office Patented June 21, 1966 1. 2 nounced, chloral hydrate, a powerful hypnotic, has been 3,257.276 utilized. The use of the more potent local anesthetic ORAL ANALGESEC PREPARATION compounds have been deplored because of their pro Robert H. Broh-Kahn, Hastings on Hudson, and Ernest. nounced tendency to cause allergic reactions. Sasmor, Yonkers, N.Y., assignors to Laboratories fo Painful conditions peculiar to the gingivae and mucosal Pharmaceutical Development, Inc., a corporation of membranes in and about the oral cavity are well known. New York Relief of pain associated with these conditions has been No Drawing. Filed Apr. 26, 1962, Ser. No. 190,235 an especially difficult problem. Thus, the commonly 8 Claims. (C. 167-65) practiced dental, surgical procedure of multiple extraction This invention relates to an improved medicinal com of diseased teeth has created problems of effective pain position adapted for use on the gingival and lip surfaces 10 control during the post-operative period. A wide area as well as on the mucosa of the buccal and oral cavity of gingival tissue becomes painful and generally exhibits in general, said surfaces and mucosa being referred to a local inflammatory response to the Surgical trauma. herein as the “oral mucosa," in order to achieve relief of When a large number of teeth are extracted at one time, pain. In particular, it is concerned with the use of or 5 the practice of suturing the wound in order to prevent ex ganic or inorganic water soluble salicylates, as for ex cessive bleeding, gives rise to prolonged pain during the ample, choline salicylate, sodium salicylate, potassium postoperative period.
    [Show full text]
  • Opinion on Salicylic Acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019
    SCCS/1601/18 Final Opinion Corrigendum of 20-21 June 2019 Scientific Committee on Consumer Safety SCCS OPINION ON salicylic acid (CAS 69-72-7) Submission I The SCCS adopted the final Opinion by written procedure on 21 December 2018 Corrigendum of 20-21 June 2019 SCCS/1601/18 Final Opinion Opinion on salicylic acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019 ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final Opinion The SCCS members: Dr U. Bernauer Dr L. Bodin Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri (Rapporteur) Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven External experts: Dr A. Simonnard Dr A. Koutsodimou Prof. W. Uter The additional contribution of the following external expert is gratefully acknowledged: Dr. N. von Goetz All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 10 September until 14 November 2018). Comments received during this time were considered by the SCCS. For this Opinion, comments received resulted in the following main changes: sections 3.3.1.1.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Prescription Medications, Drugs, Herbs & Chemicals Associated With
    Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, or by any means, without the prior written permission of the American Tinnitus Association. ©2013 American Tinnitus Association Prescription Medications, Drugs, Herbs & Chemicals Associated with Tinnitus American Tinnitus Association This document is to be utilized as a conversation tool with your health care provider and is by no means a “complete” listing. Anyone reading this list of ototoxic drugs is strongly advised NOT to discontinue taking any prescribed medication without first contacting the prescribing physician. Just because a drug is listed does not mean that you will automatically get tinnitus, or exacerbate exisiting tinnitus, if you take it. A few will, but many will not. Whether or not you eperience tinnitus after taking one of the listed drugs or herbals, or after being exposed to one of the listed chemicals, depends on many factors ‐ such as your own body chemistry, your sensitivity to drugs, the dose you take, or the length of time you take the drug. It is important to note that there may be drugs NOT listed here that could still cause tinnitus. Although this list is one of the most complete listings of drugs associated with tinnitus, no list of this kind can ever be totally complete – therefore use it as a guide and resource, but do not take it as the final word. The drug brand name is italicized and is followed by the generic drug name in bold.
    [Show full text]
  • Imports of Benzenoid Chemicals and Products 1978
    IMPORTS OF BENZENOID CHEMICALS AND PRODUCTS 1978 United States General Imports of Intermediates, Dyes, Medicinals, Flavor and Perfume Materials, and other Finished Benzenoid Products Enterered in 1978 Under Schedule 4, Part 1, of the Tariff Schedules of the United States USITC PUBLICATION 990 JULY 1979 United States International Trade Commission / Washington, D.C. 20436 UNITED STATES INTERNATIONAL TRADE COMMISSION COMMISSIONERS Joseph 0. Parker, Chairman Bill Alberger, Vice Chairman George M. Moore Catherine Bedell Paula Stern Kenneth R. Mason, Secretary to the Commission OFFICE OF INDUSTRIES Norris A. Lynch, Director This report was principally prepared by Frances Battle, Judy Bryant, Ralph Gray, Sharon Greenfield, Linda Mudd, Mildred Higgs, and Kenneth Kozel, of the Energy and Chemicals Division, and Irwin Kirshenbaum and Anthony Notar of the New York Office. Automatic Data Processing input was provided by James Gill and Dean Stout. Address all communications to Office of the Secretary United States International Trade Commission Washington, D.C. 20436 STATISTICAL TABLES Imports under TSUS, Schedule 4, Parts 1B and 1C Page 1. Benzenoid intermediates: U.S. general imports entered under pt. 1B, of the TSUS, by competitive status, 1978 6 2. Benzenoid intermediates: U.S. general imports entered under pt. 1B, of the TSUS, by sources, 1978 and 1977 6 3. Benzenoid intermediates: U.S. general imports entered under pt. 1B, of the TSUS, by competitive status, 1978 8 4. Finished benzenoid products: U.S. general imports entered under pt. 1C, TSUS, by competitive status, 1978 33 5 Finished benzenoid products: U.S. general imports entered under pt. 1C, of the TSUS, by sources, 1978 and 1977 34 6.
    [Show full text]
  • Opinion on Methyl Salicylate (Methyl 2-Hydroxybenzoate)
    SCCS/1633/21 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Scientific Committee on Consumer Safety 15 16 SCCS 17 18 19 20 21 OPINION 22 on Methyl salicylate 23 24 (methyl 2-hydroxybenzoate) 25 26 27 28 29 30 31 32 33 34 35 36 The SCCS adopted this document 37 at its plenary meeting on 24-25 June 2021 38 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 ACKNOWLEDGMENTS 3 4 Members of the Working Group are acknowledged for their valuable contribution to this Opinion. 5 The members of the Working Group are: 6 7 8 For the preliminary version 9 10 SCCS members 11 Dr U. Bernauer 12 Dr L. Bodin 13 Prof. Q. Chaudhry (SCCS Chair) 14 Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) 15 Prof. M. Dusinska 16 Dr J. Ezendam 17 Dr E. Gaffet 18 Prof. C. L. Galli 19 Dr B. Granum 20 Prof. E. Panteri 21 Prof. V. Rogiers (SCCS Vice-Chair) 22 Dr Ch. Rousselle (Rapporteur) 23 Dr M. Stepnik 24 Prof. T. Vanhaecke 25 Dr S. Wijnhoven 26 27 SCCS external experts 28 Dr A. Koutsodimou 29 Prof. W. Uter 30 Dr N. von Goetz 31 32 33 34 35 36 37 38 39 40 41 42 All Declarations of Working Group members are available on the following webpage: 43 Register of Commission expert groups and other similar entities (europa.eu) 44 45 46 47 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 1.
    [Show full text]
  • MUE/MUS), Version 1 November 11, 2016
    HCHS/SOL Visit 2 Question by Question Instructions Medication Use Form (MUE/MUS), Version 1 November 11, 2016 General Instructions The purpose of the Medication Use Questionnaire is to assess medication usage in the four weeks preceding the examination date. Information on both prescription and over-the-counter medications is ascertained. To obtain this information, the participant is asked prior to the clinic visit to bring to the field center all prescription and over-the-counter medications taken in the four-week period preceding the visit, or their containers. This request is mailed to the participant with the written instructions for the exam visit, and is re-stated during the appointment reminder call. Paper data entry and subsequent keying will only be used in the event of CDART inaccessibility. Header and administrative information are generated by the system. Question by Question Instructions Part A. Reception As the participant delivers the medications, tag the medications bag with the participant’s name and SOL ID, and ask whether any of the medications should be kept refrigerated. Indicate to the participant where the medications will be securely stored (or refrigerated), who will have access to them, and how they will be returned before he/she leaves. Mention that medication names will be copied from the labels, and that if required, medications will be taken out of their container only in the presence of, or with approval of the participant. Finally, indicate that a trained interviewer will later ask a few questions about medications use. Do not open the medications bag or transcribe medications until the participant has signed the informed consent.
    [Show full text]